1.Date of occurrence of the event: 2022/07/27
2.Company name: Adimmune Corporation
3.Relationship with the Company (please enter "the company itself" or
"subsidiaries"): The company itself
4.Reciprocal shareholding percentage: N/A
5.Name of the reporting media: Economic Daily News
6.Content of the report: "With the rising monthly revenue and the growing
shipment of influenza vaccine for the orders from international pharmas,
the monthly revenue of July is rocketing, and those of August and September
will go up even more." "The Company said...institutional investors
estimated that the revenue of July will be boosted by the increasing
international orders. The second half of 2022 revenue will reach NT$1.7
billion, exceeding that of the entire 2021."
7.Cause of occurrence: The Company is requested by TWSE to clarify mass
media reporting on 2022/07/29.
8.Countermeasures: The company's clarification is as follows:
(1) On account of the current shipment, the July revenue to be announced
is likely to strike a year-over-year record high. In addition, as Q3 is
usually the peak shipment season for influenza vaccine, the revenue of
August and September is expected to be better.
(2) In the report, "The second half of 2022 revenue will reach NT$1.7
billion, exceeding that of the entire 2021." is speculated by the press.
(3) In the report, regarding the improvement of yield rate, the shipment to
in Eastern Europe, and the launch of the third filling line in the second
half of 2023, any specific results will be announced under regulation
through material information. Investors shall refer to the actual
information submitted under regulation by the Company to MOPS.
9.Any other matters that need to be specified:
The Company didn't provide nor reveal financial information. For actual
financial information and sales, the figures on MOPS shall take precedence.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Adimmune Corporation published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 07:41:05 UTC.
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
ADIMMUNE CORPORATION 
